In a groundbreaking move for CNS drug development, PRISYS Biotech has unveiled Asia's first intraprocedural MRI (iMRI) system. This state-of-the-art technology marks a significant leap forward in precision medicine, enabling meticulous brain targeting and micro-infusion with real-time monitoring during stereotactic surgical procedures.
Specializing in Non-Human Primate (NHP) models, PRISYS Biotech has positioned itself at the forefront of research and development. The installation of the iMRI system earlier this year represents a pivotal moment in the quest to enhance therapeutic efficacy and safety in treating complex neurological conditions.
Precision and Expertise
Under the guidance of international specialists, PRISYS Biotech has perfected iMRI procedures to ensure unparalleled accuracy in targeting deep brain structures. This precision is critical for addressing structure-specific diseases, where targeted delivery of therapeutics can significantly enhance treatment outcomes.
Optimizing Therapeutic Delivery
The ability to infuse therapeutics directly into targeted brain regions revolutionizes treatment strategies. By bypassing traditional systemic delivery routes, iMRI minimizes the risk of systemic toxicity and off-target effects. This targeted approach not only improves safety profiles but also enhances the efficacy of treatments, setting a new standard in neurological care.
Advanced Technology for Advanced Solutions
PRISYS Biotech's iMRI system incorporates cutting-edge delivery devices that support diverse dosing strategies for Cell & Gene Therapies. From administering low volumes to targeting multiple sites with single or repeated injections, the technology expands the possibilities for treating neurological disorders.
Facilitating Translational Research
Integration of iMRI technology into drug development pipelines streamlines the journey from preclinical studies to clinical trials. This seamless transition encompasses human procedures, device optimization, target validation, pharmacological studies, and endpoint evaluations, ensuring robust scientific validation at every stage.
Driving Innovation Forward
PRISYS Biotech remains committed to driving innovation in CNS drug development through continuous advancements in technology and scientific expertise. As pioneers in the field, they continue to redefine possibilities in treating neurological disorders, promising new hope for patients worldwide.
For more information on PRISYS Biotech's groundbreaking iMRI technology and recent developments in CNS drug research, Click on our website and stay updated with the latest news and breakthroughs in the field.
Recent Breakthroughs in Gene Therapy for reference
Recent breakthroughs in gene therapy have demonstrated significant advancements in treating neurological disorders:
1. AMT-130 IA Update: This update showcases advancements in gene therapy technology, highlighting its potential in treating specific neurological conditions. The therapy's development emphasizes precision and efficacy in targeting disease mechanisms, reflecting broader industry progress in therapeutic innovation.
https://www.uniqure.com/assets/uploads/AMT-130-IA-update-July-2024.pdf
2. Bayer's AB-1005 for Parkinson's Disease: Bayer's investigational therapy, AB-1005, has received FDA Fast Track designation for its potential in treating Parkinson's disease. This therapy leverages gene therapy to address specific disease pathways, demonstrating how targeted approaches can enhance treatment outcomes.
https://www.bayer.com/media/en-us/askbio-receives-fda-fast-track-and-mhra-innovation-passport-designations-for-ab-1005-investigational-gdnf-gene-therapy-for-parkinsons-disease/
